Chronic kidney disease

@article{KalantarZadeh2021ChronicKD,
  title={Chronic kidney disease},
  author={Kamyar Kalantar-Zadeh and Tazeen Hasan Jafar and Dorothea Nitsch and Brendon L. Neuen and Vlado Perkovic},
  journal={The Lancet},
  year={2021},
  volume={398},
  pages={786-802}
}
View on Elsevier
researchonline.lshtm.ac.uk
36 Citations
Highly Influential Citations
1
Background Citations
14

Figures and Tables from this paper

36 Citations

Recent advances of gut microbiota in chronic kidney disease patients
TLDR
Treatment with prebiotics, probiotics and natural products can attenuate CKD through improving dysbiosis of gut microbiota, indicating a novel intervention strategy in patients with CKD.
Regulation and Potential Biological Role of Fibroblast Growth Factor 21 in Chronic Kidney Disease
TLDR
The biological characteristics, regulation and biological function of FGF21 are summarized based on the current studies, and the potential relationship with chronic kidney disease is discussed.
Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors
TLDR
Patients with autoimmune disease were excluded from all recent large renal outcome trials with SGLT-2i and given their strong nephroprotective potential are advocated to study this unique class of disease-modifying therapies when it comes to kidney and cardiovascular health in patients with AAV and LN.
Lifestyle and chronic kidney disease: A machine learning modeling study
TLDR
A lifestyle scoring system for CKD prevention was established and individuals could flexibly choose healthy lifestyles and avoid unhealthy lifestyles to prevent CKD.
The Intestinal Microbiota and Metabolites in the Gut-Kidney-Heart Axis of Chronic Kidney Disease
TLDR
The interactions between the gut, kidney and heart in CKD state are discussed, and the significant role of intestinal microbiota in the gut-kidney-heart axis hypothesis is elucidated for the pathophysiological mechanisms of these diseases.
Targeted inhibition of TGF-β type I receptor by AZ12601011 protects against kidney fibrosis.
A Survey Study on Soy Food Consumption in Patients with Chronic Kidney Diseases
  • L. Fang, Yating Du, X. Rao
  • Medicine
    Inquiry : a journal of medical care organization, provision and financing
  • 2022
TLDR
Evidence-based updated education of patients and medical workers on soy foods would be a necessary strategy for improving nutrition status of CKD patients and their clinical outcomes.
Higher Soluble ACE2 Levels and Increased Risk of Infection-Related Hospitalization in Patients on Maintenance Hemodialysis
TLDR
Higher soluble ACE2 levels may associate with an increased risk of infection-related hospitalization in patients on maintenance hemodialysis, and there were no significant associations between solubleACE2 and risks of all-cause death and CVD.
Paeoniflorin Ameliorates Skeletal Muscle Atrophy in Chronic Kidney Disease via AMPK/SIRT1/PGC-1α-Mediated Oxidative Stress and Mitochondrial Dysfunction
TLDR
It is shown for the first time that paeoniflorin has great therapeutic potential for CKD skeletal muscle atrophy through AMPK/SIRT1/PGC-1α-mediated oxidative stress and mitochondrial dysfunction.
Aryl hydrocarbon receptor: From pathogenesis to therapeutic targets in aging-related tissue fibrosis
...
...

References

SHOWING 1-10 OF 273 REFERENCES
Diabetic Kidney Disease: Challenges, Progress, and Possibilities.
TLDR
Widespread innovation is urgently needed to improve health outcomes for patients with diabetic kidney disease, and characterization of new biomarkers, designing clinical trials that evaluate clinically pertinent end points, and development of therapeutic agents targeting kidney-specific disease mechanisms are needed.
Chronic Kidney Disease
Hypertension in CKD: Core Curriculum 2019.
TLDR
Althoughintensive BP control has not been shown in clinical trials to slow the progression of CKD, intensive BP control reduces the risk for adverse cardiovascular outcomes and mortality in the CKD population.
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
TLDR
There is a rationale for studying the cardio-renal effects of SGLT-2 inhibition in people at risk of CV disease and hyperfiltration, irrespective of whether they have diabetes.
The global burden of chronic kidney disease
Novel conservative management of chronic kidney disease via dialysis-free interventions
TLDR
As dialysis may not confer better survival nor improved patient-centered outcomes in certain patients, conservative management is a viable treatment option in the advanced CKD population.
Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.
TLDR
The gut microbiome is a major contributor to adverse cardiovascular outcomes and progression of CKD and the evidence supporting a role for gut-derived uremic toxins in promoting multiorgan dysfunction via inflammatory, oxidative stress, and apoptosis pathways is discussed.
Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.
Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease
TLDR
Evidence suggests that a patient-centered plant-dominant low-protein diet (PLADO) of 0.6–0.8 g/kg/day composed of >50% plant-based sources, administered by dietitians trained in non-dialysis CKD care, is promising and consistent with the precision nutrition.
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
...
...